Vital Life and Huawei have partnered in health technology to develop a project studying the risk assessment of "high blood sugar" through wearable devices. The first device model is set to launch soon in Thailand.
The Vital Life Health Promotion Center, part of Bumrungrad Hospital, announced its cooperation with Huawei Consumer Business Group Thailand to advance digital health technology capabilities through a project assessing the risk of high blood sugar using Huawei smartwatches. This supports proactive health care and drives the application of health innovations in Thailand.
This collaboration marks a significant milestone reflecting Huawei's vision to elevate wearable technology beyond daily health tracking tools to become part of the digital health infrastructure. It can effectively support preventive health care and improve accessibility by integrating advanced sensor technology, health data analysis, and medical expertise from leading partners. The project assessing the risk of high blood sugar is an important step in empowering consumers to recognize and understand their health risks early. It also promotes proactive health management approaches that are practical and tailored to modern lifestyles.
This project builds on Huawei's ongoing health research in China through the Huawei Research Platform, covering multiple health dimensions such as heart health, respiration, liver health, hypertension, and other topics. Huawei has collaborated with over 170 research organizations and reached more than 17 million users, reinforcing confidence that wearable device data can offer value beyond exercise tracking, extending to future health care knowledge and research development.
Building on prior successful research in China, the project assessing high blood sugar risk is Huawei’s first effort to introduce this type of health study internationally. Its goal is to make preliminary risk screening more accessible via wearable devices and help users become aware of their health risks sooner.
In this project, when users enroll and provide consent as required, the system collects health data from their wearable devices over a set period. This data is analyzed to provide an initial risk assessment, which may be presented as low risk, high risk, or no initial risk. This helps participants appropriately and promptly understand their health information, supporting the study’s accuracy and scientific value.
Some participants may be contacted by the hospital to cooperate in further blood sugar level testing. These clinical results will be used to compare with smartwatch data to improve and refine the risk assessment model, aiming to increase its accuracy above 90% in the future.
The collaboration also aims to leverage study findings to foster academic and industry exchanges that enhance understanding of preventive health and strengthen Thailand’s health technology ecosystem for sustainable growth.
The first device driving this project is the HUAWEI WATCH FIT 5 Pro, set to launch soon in Thailand. This wearable will be the initial model used, reflecting Huawei’s role in advancing wearables beyond fitness smartwatches to part of a digital health ecosystem supporting proactive daily health care. It integrates sensor technology, health data, and research platforms to make health management more accessible to modern consumers.
It should be noted that the wearable devices used in this project are intended for observational and research purposes only and are not meant to replace medical diagnosis, treatment, or professional medical advice.